Carlo Andrea Pivato

Carlo Andrea Pivato

Auto-generated profile, based on publicly available information

Carlo Andrea Pivato

Department of Biomedical Sciences, Humanitas University , Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in International Journal of Cardiology
Verified
Journal Article
Closed access
CGCosmo Godino
Cosmo Godino
Andrea ScottiAndrea Scotti
Andrea Scotti
MTMaurizio Taramasso
Maurizio Taramasso
MAMarianna Adamo
Marianna Adamo
MRMarco Russo
Marco Russo
ACAntonio Colombo
Antonio Colombo

11 January 2022 in European Heart Journal - Cardiovascular Pharmacotherapy
Verified
Journal Article
Closed access
VRVictor Razuk
Victor Razuk
MCMauro Chiarito
Mauro Chiarito
DCDavide Cao
Davide Cao
JNJohny Nicolas
Johny Nicolas
CPCarlo A Pivato
Carlo A Pivato
RMRoxana Mehran
Roxana Mehran
Aims: Sodium–glucose cotransporter 2 (SGLT-2) inhibitors have cardiovascular (CV) benefits in patients with heart failure with reduced ejection fraction (HFrEF). Whether these medications improve CV outcomes irrespective of heart failure history or left ventricular ejection fraction (LVEF) in HFrEF remains unknown. Methods and results: All randomized, placebo-controlled trials of SGLT-2 inhibitors reporting similar CV outcomes were searched in PubMed from 1 January 2010 to 1 October 2021. The primary outcome was the composite of hospitalization for heart failure or CV death. Secondary outcomes included all-cause mortality. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used as effect estimates and calculated with a random-effects model. Data from 11 trials and a total of 66 957 patients (n = 36 758 SGLT-2 group, n = 30 199 placebo group) were included. SGLT-2 inhibitors reduced the risk of hospitalization for heart failure or CV death in patients with (HR 0.76, 95% CI 0.71–0.80) and without (HR 0.76, 95% CI 0.68–0.86; Pinteraction = 0.69) heart failure. Patients with (HR 0.87, 95% CI 0.80–0.95) and without (HR 0.84, 95% CI 0.73–0.95; Pinteraction = 0.67) heart failure treated with SGLT-2 inhibitors had a reduction in all-cause mortality. Reduction in the primary outcome was consistently observed in HFrEF patients with (HR 0.68, 95% CI 0.59–0.78) and without (HR 0.84, 95% CI 0.71–0.99; Pinteraction = 0.13) severely reduced LVEF, and in heart failure with preserved ejection fraction patients (HR 0.80, 95% CI 0.70–0.92; Pinteraction = 0.65). Conclusion: SGLT-2 inhibitors improved CV outcomes irrespective of heart failure history or type, and severity of LVEF reduction.

1 February 2019 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
MCMauro Chiarito
Mauro Chiarito
GSGennaro Sardella
Gennaro Sardella
ACAntonio Colombo
Antonio Colombo
CBCarlo Briguori
Carlo Briguori
Luca TestaLuca Testa
Luca Testa
GSGiulio G Stefanini
Giulio G Stefanini
Background: Polymer-free drug-eluting stents are based on different technologies for drug binding and release without the use of polymer coatings. It is unknown whether different polymer-free drug-eluting stents are comparable in terms of safety and efficacy profiles. Methods and Results: Polymer-free BioFreedom biolimus-eluting stents (BES) and polymer-free Cre8 amphilimus-eluting stents (AES) were investigated in 2 recent multicenter registries including 2320 all-comer patients undergoing percutaneous coronary interventions at 22 Italian centers. Using propensity score matching, safety and efficacy outcomes were compared among 1280 patients (640 matched pairs) treated with BioFreedom BES or Cre8 AES. The primary end point was target lesion failure—a composite of cardiac death, target vessel myocardial infarction, and target lesion revascularization (TLR). At 1 year, target lesion failure occurred in 4.0% of BES and 4.2% of AES-treated patients (hazard ratio [HR] 0.98, 95% CI, 0.57–1.70). Risks of cardiac death (2.0% versus 2.1%; HR, 1.03; 95% CI, 0.47–2.26), target vessel myocardial infarction (0.8% versus 0.3%; HR, 1.89; 95% CI, 0.50–6.80), TLR (1.5% versus 2.2%; HR, 0.74; 95% CI, 0.34–1.62), and definite/probable stent thrombosis (0.9% versus 0.8%; HR, 1.17; 95% CI, 0.36–3.81) were comparable in patients treated with BioFreedom BES and Cre8 AES. A differential treatment effect by diabetes mellitus status was observed, indicating a benefit of AES in patients with diabetes mellitus ( P interaction=0.003). Conclusions: The present study shows that BioFreedom BES and Cre8 AES have favorable and comparable safety and efficacy profiles in all-comer patients undergoing percutaneous coronary intervention. Further evaluation in large-scale, randomized trials are necessary to confirm our findings.

1 April 2020 in EuroIntervention
Verified
Journal Article
Closed access
CGCosmo Godino
Cosmo Godino
FMFrancesco Melillo
Francesco Melillo
BBBarbara Bellini
Barbara Bellini
MMMattia Mazzucca
Mattia Mazzucca
CPCarlo Andrea Pivato
Carlo Andrea Pivato
MMMatteo Montorfano
Matteo Montorfano
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

21 February 2019 in Heart
Verified
Journal Article
Closed access
PDF file
CGCosmo Godino
Cosmo Godino
AGAlessia Giannattasio
Alessia Giannattasio
Andrea ScottiAndrea Scotti
Andrea Scotti
LBLuca Baldetti
Luca Baldetti
CPCarlo Andrea Pivato
Carlo Andrea Pivato
ACAntonio Colombo
Antonio Colombo
Objective The aim of this study is to evaluate the long-term risk of cardiac death and sudden cardiac death (SCD) and/or sustained ventricular arrhythmias (SVAs) in patients with coronary chronic total occlusions (CTO) revascularised versus those with CTO not revascularised by percutaneous coronary intervention (PCI). Methods From a cohort of 1357 CTO-PCI patients, 1162 patients who underwent CTO PCI attempt were included in this long-term analysis: 837 patients were revascularised by PCI (CTO-R group) and 325 were not revascularised (CTO-NR group). Primary adverse endpoint was the incidence of cardiac death; secondary endpoint was the cumulative incidence of SCD/SVAs. Results Up to 12-year follow-up (median 6 year), compared with CTO-R patients, those with CTO-NR had significantly higher rate of cardiac death (13%[43/325]vs6%[48/837]; p<0.001) and SCD/SVAs (7.5%[24/325]vs2.5%[20/837]; p<0.001). The risk of cardiac death and SCD/SVAs was mainly driven by the subgroup of infarct-related artery (IRA) CTO patients and was significantly higher only in IRA CTO-NR patients (18%vs7%, p2-fold risk of cardiac death and threefold risk of SCD/SVAs. The presence of an infarct-related artery (IRA CTO) not revascularised identified the category of patients with the highest rate of adverse events .

15 March 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
CPCarlo A. Pivato
Carlo A. Pivato
BRBernhard Reimers
Bernhard Reimers
Luca TestaLuca Testa
Luca Testa
APAndrea Pacchioni
Andrea Pacchioni
Carlo BriguoriCarlo Briguori
Carlo Briguori
GSGiulio G Stefanini
Giulio G Stefanini
Background: It is unknown whether contemporary drug‐eluting stents have a similar safety profile in high bleeding risk patients treated with 1‐month dual antiplatelet therapy following percutaneous coronary interventions. Methods and Results: We performed an interventional, prospective, multicenter, single‐arm trial, powered for noninferiority with respect to an objective performance criterion to evaluate the safety of percutaneous coronary interventions with Synergy bioresorbable‐polymer everolimus‐eluting stent followed by 1‐month dual antiplatelet therapy in patients with high bleeding risk. In case of need for an oral anticoagulant, patients received an oral anticoagulant in addition to a P2Y 12 inhibitor for 1 month, followed by an oral anticoagulant only. The primary end point was the composite of cardiac death, myocardial infarction, or definite or probable stent thrombosis at 1‐year follow‐up. The study was prematurely interrupted because of slow recruitment. From April 2017 to October 2019, 443 patients (age, 74.8±9.2 years; women, 29.1%) at 10 Italian centers were included. The 1‐year primary outcome occurred in 4.82% (95% CI, 3.17%–7.31%) of patients, meeting the noninferiority compared with the predefined objective performance criterion of 9.4% and the noninferiority margin of 3.85% ( P noninferiority <0.001) notwithstanding the lower‐than‐expected sample size. The rates of cardiac death, myocardial infarction, and definite or probable stent thrombosis were 1.88% (95% CI, 0.36%–2.50%), 3.42% (95% CI, 2.08%–5.62%), and 0.94% (95% CI, 0.35%–2.49%), respectively. Conclusions: Among high bleeding risk patients undergoing percutaneous coronary interventions with the Synergy bioresorbable‐polymer everolimus‐eluting stent, a 1‐month dual antiplatelet therapy regimen is safe, with low rates of ischemic and bleeding events. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03112707 .